Stemline Therapeutics (NASDAQ:STML) is set to post its quarterly earnings results after the market closes on Wednesday, March 14th. Analysts expect Stemline Therapeutics to post earnings of ($0.70) per share for the quarter.
Shares of Stemline Therapeutics (STML) opened at $17.40 on Tuesday. The company has a market cap of $504.11, a price-to-earnings ratio of -6.77 and a beta of -0.07. Stemline Therapeutics has a 12 month low of $7.30 and a 12 month high of $18.75.
A number of analysts have commented on the stock. ValuEngine cut shares of Stemline Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, March 7th. BidaskClub upgraded shares of Stemline Therapeutics from a “hold” rating to a “buy” rating in a research note on Thursday, January 4th. Zacks Investment Research cut shares of Stemline Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, February 9th. Finally, HC Wainwright reiterated a “buy” rating and issued a $38.00 price target on shares of Stemline Therapeutics in a research note on Friday, February 2nd. Two research analysts have rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $33.75.
An institutional investor recently raised its position in Stemline Therapeutics stock. The Manufacturers Life Insurance Company grew its stake in Stemline Therapeutics Inc (NASDAQ:STML) by 40.1% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 19,279 shares of the biopharmaceutical company’s stock after purchasing an additional 5,522 shares during the quarter. The Manufacturers Life Insurance Company owned approximately 0.08% of Stemline Therapeutics worth $178,000 as of its most recent SEC filing. Institutional investors and hedge funds own 52.09% of the company’s stock.
Stemline Therapeutics Company Profile
Stemline Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) (CD123), present on a range of hematologic cancers.
Receive News & Ratings for Stemline Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.